ArticleBreast (Edinburgh, Scotland)2025
Evaluation of breast cancer screening programmes: Candidate performance indicators and their association with breast cancer mortality.
Article in Breast (Edinburgh, Scotland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Determinants of Early-Stage Breast Cancer Presentation in Western Kazakhstan: A Population-Based Analysis of Urban-Rural Disparities and Diagnostic Pathways (2015-2025).Medicina (Kaunas, Lithuania) · 2026Article
- Socio-Demographic Inequalities in Diagnostic Delays of Breast Cancer: A Multistage Time-to-Diagnosis Analysis.Current oncology (Toronto, Ont.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
aimEvaluation of a breast cancer (BC) screening programme is necessary to ensure its quality. Performance measurements might be prioritized considering the association with outcomes related to BC mortality. We piloted an approach to explore the association of selected performance measurements with incidence-based BC mortality (IBM).
methodsWe performed an ecological analysis of aggregated data from regional or national population-based cancer registries and BC screening programmes in Europe, using 13 performance indicators. We built a panel data (longitudinal cross-sectional) regression model to estimate the association between screening performance measurements and IBM rates.
resultsWe included data of 9 programmes and registries from Italy, Spain, Norway, Ireland and the Czech Republic. The number of screening years included in the dataset ranged from 5 to 20 years. In adjusted panel analyses, higher screening coverage, breast cancer detection rates (BCDR prevalent and subsequent rounds), node-negative proportion, and episode sensitivity were associated with lower incidence-based mortality (IBM), whereas a higher interval cancer rate was associated with higher IBM. The association for recall rate in subsequent examinations was small and imprecise.
conclusionOur pilot approach suggests association of several performance indicators with IBM. These indicators were related to the implementation of the screening programme (screening coverage), sensitivity (BC detection rate), and efficiency (recall rate). Further studies with larger datasets and individual data may confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.